Basic Information
Adela aims to detect cancer and other high-incidence, high-mortality diseases by utilizing blood tests with methylation potential. Adela's whole-genome methylation enrichment technology offers the potential for large-scale detection of multiple diseases through a single test, with superior performance.
ADELA, Inc.
California,United States of America
51~100 people
January 01, 2020
info@adelabio.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios